

Robert Nistico

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8824739/publications.pdf>

Version: 2024-02-01

141
papers

5,157
citations

87401

40
h-index

129628

63
g-index

142
all docs

142
docs citations

142
times ranked

8435
citing authors

#	ARTICLE	IF	CITATIONS
1	The changing landscape of treatment options in childhood acute lymphoblastic leukaemia. <i>Drug Discovery Today</i> , 2022, , .	3.2	4
2	Exploiting Focused Ultrasound to Aid Intranasal Drug Delivery for Brain Therapy. <i>Frontiers in Pharmacology</i> , 2022, 13, 786475.	1.6	3
3	Defining and assessing intrinsic capacity in older people: A systematic review and a proposed scoring system. <i>Ageing Research Reviews</i> , 2022, 79, 101640.	5.0	30
4	Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery. <i>Neuropharmacology</i> , 2021, 185, 108081.	2.0	27
5	The β -Secretase BACE1 in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2021, 89, 745-756.	0.7	336
6	Targeting Microglia-Synapse Interactions in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2342.	1.8	36
7	Physical Exercise and Alzheimer's Disease: Effects on Pathophysiological Molecular Pathways of the Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2897.	1.8	30
8	A Healthy Gut for a Healthy Brain: Preclinical, Clinical and Regulatory Aspects. <i>Current Neuropharmacology</i> , 2021, 19, 610-628.	1.4	15
9	Omics sciences for systems biology in Alzheimer's disease: State-of-the-art of the evidence. <i>Ageing Research Reviews</i> , 2021, 69, 101346.	5.0	74
10	Defining Satisfactory Methods of Treatment in Rare Diseases When Evaluating Significant Benefit—The EU Regulator's Perspective. <i>Frontiers in Medicine</i> , 2021, 8, 744625.	1.2	3
11	Exercise interventions in Alzheimer's disease: A systematic review and meta-analysis of randomized controlled trials. <i>Ageing Research Reviews</i> , 2021, 72, 101479.	5.0	48
12	Aducanumab for Alzheimer's disease: A regulatory perspective. <i>Pharmacological Research</i> , 2021, 171, 105754.	3.1	40
13	Neurodegenerative Disease: What Potential Therapeutic Role of Acid-Sensing Ion Channels?. <i>Frontiers in Cellular Neuroscience</i> , 2021, 15, 730641.	1.8	12
14	Biological Mechanism-based Neurology and Psychiatry: a BACE1/2 and Downstream Pathway Model. <i>Current Neuropharmacology</i> , 2021, 19, .	1.4	1
15	Impairment of hippocampal synaptic plasticity induced by pathological microglial activation. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
16	Nonclinical data supporting orphan medicinal product designations in the area of rare infectious diseases. <i>Drug Discovery Today</i> , 2020, 25, 274-291.	3.2	5
17	Cerebrospinal fluid and serum d-serine concentrations are unaltered across the whole clinical spectrum of Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2020, 1868, 140537.	1.1	19
18	Role of ASIC1a in Normal and Pathological Synaptic Plasticity. <i>Reviews of Physiology, Biochemistry and Pharmacology</i> , 2020, 177, 83-100.	0.9	7

#	ARTICLE	IF	CITATIONS
19	Involvement of Bradykinin Receptor 2 in Nerve Growth Factor Neuroprotective Activity. <i>Cells</i> , 2020, 9, 2651.	1.8	6
20	Reply to the reply of the authors of the review article entitled "Management of status epilepticus in adults. Position paper of the Italian League against Epilepsy". <i>Epilepsy and Behavior</i> , 2020, 110, 107168.	0.9	0
21	Reply to the article "Management of status epilepticus in adults. Position paper of the Italian League against Epilepsy". <i>Epilepsy and Behavior</i> , 2020, 107, 106866.	0.9	2
22	A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease. <i>Frontiers in Immunology</i> , 2020, 11, 456.	2.2	201
23	Effects of intranasally-delivered pro-nerve growth factors on the septo-hippocampal system in healthy and diabetic rats. <i>Neuropharmacology</i> , 2020, 176, 108223.	2.0	1
24	Targeting Synaptic Plasticity in Experimental Models of Alzheimer's Disease. <i>Frontiers in Pharmacology</i> , 2019, 10, 778.	1.6	66
25	Lithium as a Treatment for Alzheimer's Disease: The Systems Pharmacology Perspective. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 615-629.	1.2	44
26	Feedback inhibition of cAMP effector signaling by a chaperone-assisted ubiquitin system. <i>Nature Communications</i> , 2019, 10, 2572.	5.8	29
27	The selective disruption of presynaptic JNK2/STX1a interaction reduces NMDA receptor-dependent glutamate release. <i>Scientific Reports</i> , 2019, 9, 7146.	1.6	10
28	Electroacupuncture in rats normalizes the diabetes-induced alterations in the septo-hippocampal cholinergic system. <i>Hippocampus</i> , 2019, 29, 891-904.	0.9	7
29	The positive allosteric modulator at mGlu2 receptors, LY487379, reverses the effects of chronic stress-induced behavioral maladaptation and synaptic dysfunction in the adulthood. <i>Synapse</i> , 2019, 73, e22101.	0.6	5
30	Alzheimer's disease: understanding homeostasis deregulation to foster development of effective therapies. <i>Pharmacological Research</i> , 2019, 139, 467-468.	3.1	0
31	Optimising bench science to withstand regulatory scrutiny. <i>Pharmacological Research</i> , 2019, 139, 491-493.	3.1	2
32	PDGF Modulates Synaptic Excitability and Short-Latency Afferent Inhibition in Multiple Sclerosis. <i>Neurochemical Research</i> , 2019, 44, 726-733.	1.6	5
33	Early alteration of distribution and activity of hippocampal type-1 cannabinoid receptor in Alzheimer's disease-like mice overexpressing the human mutant amyloid precursor protein. <i>Pharmacological Research</i> , 2018, 130, 366-373.	3.1	19
34	Neuregulin 1/ErbB signalling modulates hippocampal mGluRI-dependent LTD and object recognition memory. <i>Pharmacological Research</i> , 2018, 130, 12-24.	3.1	21
35	Revolution of Alzheimer Precision Neurology. <i>Passageway of Systems Biology and Neurophysiology. Journal of Alzheimer's Disease</i> , 2018, 64, S47-S105.	1.2	122
36	Unlocking the secrets of dopamine in Alzheimer's Disease. <i>Pharmacological Research</i> , 2018, 128, 399.	3.1	15

#	ARTICLE	IF	CITATIONS
37	Targeting mGlu5 Metabotropic Glutamate Receptors in the Treatment of Cognitive Dysfunction in a Mouse Model of Phenylketonuria. <i>Frontiers in Neuroscience</i> , 2018, 12, 154.	1.4	10
38	Precision medicine and drug development in Alzheimer's disease: the importance of sexual dimorphism and patient stratification. <i>Frontiers in Neuroendocrinology</i> , 2018, 50, 31-51.	2.5	46
39	The Involvement of Post-Translational Modifications in Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2018, 15, 313-335.	0.7	57
40	Bromelain Degrades A β 1-42 Monomers and Soluble Aggregates: An In Vitro Study in Cerebrospinal Fluid of Alzheimer's Disease Patients. <i>Current Alzheimer Research</i> , 2018, 15, 628-636.	0.7	17
41	Gut-brain axis: Physiology and pathology. , 2018, , .		0
42	Prokineticin system modulation as a new target to counteract the amyloid beta toxicity induced by glutamatergic alterations in an in vitro model of Alzheimer's disease. <i>Neuropharmacology</i> , 2017, 116, 82-97.	2.0	21
43	Acid-sensing ion channel 1a is required for mGlu receptor dependent long-term depression in the hippocampus. <i>Pharmacological Research</i> , 2017, 119, 12-19.	3.1	18
44	The role of adiponectin receptors in the regulation of synaptic transmission in the hippocampus. <i>Synapse</i> , 2017, 71, e21964.	0.6	19
45	Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 1327-1334.	1.2	35
46	Recovery of hippocampal functions and modulation of muscarinic response by electroacupuncture in young diabetic rats. <i>Scientific Reports</i> , 2017, 7, 9077.	1.6	16
47	Synptoimmunology - roles in health and disease. <i>Molecular Brain</i> , 2017, 10, 26.	1.3	36
48	Targeting SUMO-1ylation Contrasts Synaptic Dysfunction in a Mouse Model of Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2017, 54, 6609-6623.	1.9	26
49	[P2 β]: TWO-LEVEL DIAGNOSTIC CLASSIFICATION USING CEREBROSPINAL FLUID NEUROGRANIN IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P712.	0.4	0
50	Unbalance between Excitation and Inhibition in Phenylketonuria, a Genetic Metabolic Disease Associated with Autism. <i>International Journal of Molecular Sciences</i> , 2017, 18, 941.	1.8	10
51	Ginkgolic Acid Protects against A β 2-Induced Synaptic Dysfunction in the Hippocampus. <i>Frontiers in Pharmacology</i> , 2016, 7, 401.	1.6	19
52	Xanthurenic Acid Activates mGlu2/3 Metabotropic Glutamate Receptors and is a Potential Trait Marker for Schizophrenia. <i>Scientific Reports</i> , 2016, 5, 17799.	1.6	91
53	NGF controls APP cleavage by downregulating APP phosphorylation at Thr668: relevance for Alzheimer's disease. <i>Aging Cell</i> , 2016, 15, 661-672.	3.0	57
54	Subtle alterations of excitatory transmission are linked to presynaptic changes in the hippocampus of PINK1-deficient mice. <i>Synapse</i> , 2016, 70, 223-230.	0.6	14

#	ARTICLE	IF	CITATIONS
55	Gender difference in prescription opioid abuse: A focus on oxycodone and hydrocodone. <i>Pharmacological Research</i> , 2016, 108, 31-38.	3.1	16
56	RANTES correlates with inflammatory activity and synaptic excitability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1405-1412.	1.4	46
57	Inhibition of hippocampal plasticity in rats performing contrafreeloading for water under repeated administrations of pramipexole. <i>Psychopharmacology</i> , 2016, 233, 727-737.	1.5	7
58	Rhes influences striatal cAMP/PKA-dependent signaling and synaptic plasticity in a gender-sensitive fashion. <i>Scientific Reports</i> , 2015, 5, 10933.	1.6	38
59	Bv8/prokineticin 2 is involved in $A\beta$ -induced neurotoxicity. <i>Scientific Reports</i> , 2015, 5, 15301.	1.6	40
60	Gender differences in pharmacokinetics and pharmacodynamics of methadone substitution therapy. <i>Frontiers in Pharmacology</i> , 2015, 6, 122.	1.6	16
61	5-HT _{2C} serotonin receptor blockade prevents tau protein hyperphosphorylation and corrects the defect in hippocampal synaptic plasticity caused by a combination of environmental stressors in mice. <i>Pharmacological Research</i> , 2015, 99, 258-268.	3.1	18
62	d-Aspartate oxidase influences glutamatergic system homeostasis in mammalian brain. <i>Neurobiology of Aging</i> , 2015, 36, 1890-1902.	1.5	42
63	Presynaptic c-Jun N-terminal Kinase 2 regulates NMDA receptor-dependent glutamate release. <i>Scientific Reports</i> , 2015, 5, 9035.	1.6	41
64	Stress dynamically regulates behavior and glutamatergic gene expression in hippocampus by opening a window of epigenetic plasticity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 14960-14965.	3.3	121
65	Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 83-105.	1.4	64
66	Age-related changes of protein SUMOylation balance in the A β PP Tg2576 mouse model of Alzheimer's disease. <i>Frontiers in Pharmacology</i> , 2014, 5, 63.	1.6	42
67	Free D-aspartate regulates neuronal dendritic morphology, synaptic plasticity, gray matter volume and brain activity in mammals. <i>Translational Psychiatry</i> , 2014, 4, e417-e417.	2.4	47
68	Regional specificity of synaptic plasticity deficits in a knock-in mouse model of DYT1 dystonia. <i>Neurobiology of Disease</i> , 2014, 65, 124-132.	2.1	69
69	Interleukin-1 β Promotes Long-Term Potentiation in Patients with Multiple Sclerosis. <i>NeuroMolecular Medicine</i> , 2014, 16, 38-51.	1.8	64
70	Changes in mGlu5 Receptor-Dependent Synaptic Plasticity and Coupling to Homer Proteins in the Hippocampus of Ube3A Hemizygous Mice Modeling Angelman Syndrome. <i>Journal of Neuroscience</i> , 2014, 34, 4558-4566.	1.7	73
71	Adenosine A1 receptor stimulation reduces D1 receptor-mediated GABAergic transmission from striato-nigral terminals and attenuates l-DOPA-induced dyskinesia in dopamine-denervated mice. <i>Experimental Neurology</i> , 2014, 261, 733-743.	2.0	29
72	Genders and the concurrent use of cocaine and alcohol: Pharmacological aspects. <i>Pharmacological Research</i> , 2014, 87, 60-70.	3.1	31

#	ARTICLE	IF	CITATIONS
73	Levels of the Rab GDP dissociation inhibitor (GDI) are altered in the prenatal restrain stress mouse model of schizophrenia and are differentially regulated by the mGlu2/3 receptor agonists, LY379268 and LY354740. <i>Neuropharmacology</i> , 2014, 86, 133-144.	2.0	11
74	Synaptic plasticity in multiple sclerosis and in experimental autoimmune encephalomyelitis. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2014, 369, 20130162.	1.8	43
75	Growth Factors and Synaptic Plasticity in Relapsing—Remitting Multiple Sclerosis. <i>NeuroMolecular Medicine</i> , 2014, 16, 490-498.	1.8	18
76	Paradoxical Abatement of Striatal Dopaminergic Transmission by Cocaine and Methylphenidate. <i>Journal of Biological Chemistry</i> , 2014, 289, 264-274.	1.6	27
77	Phosphodiesterase 10A controls D1-mediated facilitation of GABA release from striato-nigral projections under normal and dopamine-depleted conditions. <i>Neuropharmacology</i> , 2014, 76, 127-136.	2.0	27
78	Selective regulation of recombinantly expressed mGlu7 metabotropic glutamate receptors by G protein-coupled receptor kinases and arrestins. <i>Neuropharmacology</i> , 2014, 77, 303-312.	2.0	27
79	Electrophysiological and metabolic effects of CHF5074 in the hippocampus: Protection against in vitro ischemia. <i>Pharmacological Research</i> , 2014, 81, 83-90.	3.1	22
80	Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020. <i>Biochemical Pharmacology</i> , 2014, 88, 426-449.	2.0	105
81	Cognitive Impairment and Dentate Gyrus Synaptic Dysfunction in Experimental Parkinsonism. <i>Biological Psychiatry</i> , 2014, 75, 701-710.	0.7	56
82	Electrophysiological and amperometric evidence that modafinil blocks the dopamine uptake transporter to induce behavioral activation. <i>Neuroscience</i> , 2013, 252, 118-124.	1.1	15
83	Calcineurin Inhibition Rescues Early Synaptic Plasticity Deficits in a Mouse Model of Alzheimer's Disease. <i>NeuroMolecular Medicine</i> , 2013, 15, 541-548.	1.8	45
84	SUMO: a (Oxidative) Stressed Protein. <i>NeuroMolecular Medicine</i> , 2013, 15, 707-719.	1.8	55
85	SUMOylation in Neuroplasticity and Neurological Disorders. <i>NeuroMolecular Medicine</i> , 2013, 15, 637-638.	1.8	4
86	Huperzine A Restores Cortico-Hippocampal Functional Connectivity after Bilateral AMPA Lesion of the Nucleus Basalis of Meynert. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 833-846.	1.2	16
87	Enhanced mGlu5-receptor dependent long-term depression at the Schaffer collateral-CA1 synapse of congenitally learned helpless rats. <i>Neuropharmacology</i> , 2013, 66, 339-347.	2.0	19
88	Single or combined treatment with L-DOPA and quinpirole differentially modulate expression and phosphorylation of key regulatory kinases in neuroblastoma cells. <i>Neuroscience Letters</i> , 2013, 552, 168-173.	1.0	0
89	Synaptic Plasticity and PDGF Signaling Defects Underlie Clinical Progression in Multiple Sclerosis. <i>Journal of Neuroscience</i> , 2013, 33, 19112-19119.	1.7	70
90	Profile of gantenerumab and its potential in the treatment of Alzheimer's disease. <i>Drug Design, Development and Therapy</i> , 2013, 7, 1359.	2.0	28

#	ARTICLE	IF	CITATIONS
91	B.11 - PRAMIPEXOLE DISRUPTS SYNAPTIC PLASTICITY IN THE CA1 AREA OF THE HIPOCAMPUS OF RATS THAT DEVELOP CONTRAFRELOADING FOR WATER, AN ANIMAL MODEL OF COMPULSIVE BEHAVIOR. Behavioural Pharmacology, 2013, 24, e29.	0.8	0
92	NS.4.2 - PRAMIPEXOLE DISRUPTS SYNAPTIC PLASTICITY IN THE CA1 AREA OF THE HIPOCAMPUS OF RATS THAT DEVELOP CONTRAFRELOADING FOR WATER, AN ANIMAL MODEL OF COMPULSIVE BEHAVIOR. Behavioural Pharmacology, 2013, 24, e21.	0.8	0
93	Editorial Thematic Issue: Targeting Synaptic Dysfunction and Neural Connectivity in Neurological and Psychiatric Disorders. Current Pharmaceutical Design, 2013, 19, 6391-6392.	0.9	1
94	Inflammation Subverts Hippocampal Synaptic Plasticity in Experimental Multiple Sclerosis. PLoS ONE, 2013, 8, e54666.	1.1	123
95	Synaptic Plasticity as a Therapeutic Target in the Treatment of Autism-related Single-gene Disorders. Current Pharmaceutical Design, 2013, 19, 6480-6490.	0.9	11
96	Targeting Synaptic Dysfunction in Alzheimer's Disease Therapy. Molecular Neurobiology, 2012, 46, 572-587.	1.9	80
97	Therapeutic potential of targeting hydrogen peroxide metabolism in the treatment of brain ischaemia. British Journal of Pharmacology, 2012, 166, 1211-1224.	2.7	58
98	Insulin Receptor β -Subunit Haploinsufficiency Impairs Hippocampal Late-Phase LTP and Recognition Memory. NeuroMolecular Medicine, 2012, 14, 262-269.	1.8	58
99	New insights on the role of free d-aspartate in the mammalian brain. Amino Acids, 2012, 43, 1861-1871.	1.2	76
100	Age-Related Changes of Hippocampal Synaptic Plasticity in β -APP-Null Mice are Restored by NGF Through p75NTR. Journal of Alzheimer's Disease, 2012, 33, 265-272.	1.2	11
101	L-DOPA: A scapegoat for accelerated neurodegeneration in Parkinson's disease?. Progress in Neurobiology, 2011, 94, 389-407.	2.8	100
102	Persistent increase of d-aspartate in d-aspartate oxidase mutant mice induces a precocious hippocampal age-dependent synaptic plasticity and spatial memory decay. Neurobiology of Aging, 2011, 32, 2061-2074.	1.5	60
103	Increased d-aspartate brain content rescues hippocampal age-related synaptic plasticity deterioration of mice. Neurobiology of Aging, 2011, 32, 2229-2243.	1.5	70
104	The β -Secretase Modulator CHF5074 Restores Memory and Hippocampal Synaptic Plasticity in Plaque-Free Tg2576 Mice. Journal of Alzheimer's Disease, 2011, 24, 799-816.	1.2	53
105	Control of PKA stability and signalling by the RING ligase praja2. Nature Cell Biology, 2011, 13, 412-422.	4.6	77
106	Na ⁺ -Ca ²⁺ Exchanger (NCX3) Knock-Out Mice Display an Impairment in Hippocampal Long-Term Potentiation and Spatial Learning and Memory. Journal of Neuroscience, 2011, 31, 7312-7321.	1.7	75
107	Synergistic interactions between kainate and mGlu receptors regulate bouton Ca ²⁺ signalling and mossy fibre LTP. Scientific Reports, 2011, 1, 103.	1.6	17
108	Characterization of gene expression induced by RTN-1C in human neuroblastoma cells and in mouse brain. Neurobiology of Disease, 2010, 40, 634-644.	2.1	6

#	ARTICLE	IF	CITATIONS
109	<i>N</i> -ethyl lidocaine (QX-314) protects striatal neurons against ischemia: An in vitro electrophysiological study. <i>Synapse</i> , 2010, 64, 161-168.	0.6	3
110	Learning discloses abnormal structural and functional plasticity at hippocampal synapses in the APP23 mouse model of Alzheimer's disease. <i>Learning and Memory</i> , 2010, 17, 236-240.	0.5	26
111	Role of Aberrant Striatal Dopamine D ₁ Receptor/cAMP/Protein Kinase A/DARPP32 Signaling in the Paradoxical Calming Effect of Amphetamine. <i>Journal of Neuroscience</i> , 2010, 30, 11043-11056.	1.7	66
112	Connexin 26 (GJB2) mutations, causing KID Syndrome, are associated with cell death due to calcium gating deregulation. <i>Biochemical and Biophysical Research Communications</i> , 2010, 394, 909-914.	1.0	33
113	Chapter 2 Gluk1 Receptor Antagonists and Hippocampal Mossy Fiber Function. <i>International Review of Neurobiology</i> , 2009, 85, 13-27.	0.9	6
114	D-Aspartate: An Atypical Amino Acid with Neuromodulatory Activity in Mammals. <i>Reviews in the Neurosciences</i> , 2009, 20, 429-40.	1.4	30
115	Chapter 25 Oxidative Stress in Stroke Pathophysiology. <i>International Review of Neurobiology</i> , 2009, 85, 363-374.	0.9	31
116	Ethanol enhances GABA _B -mediated inhibitory postsynaptic transmission on rat midbrain dopaminergic neurons by facilitating GIRK currents. <i>European Journal of Neuroscience</i> , 2009, 29, 1369-1377.	1.2	39
117	ACET is a highly potent and specific kainate receptor antagonist: Characterisation and effects on hippocampal mossy fibre function. <i>Neuropharmacology</i> , 2009, 56, 121-130.	2.0	44
118	Exploitation of the HIV-1 coat glycoprotein, gp120, in neurodegenerative studies in vivo. <i>Journal of Neurochemistry</i> , 2008, 79, 1-8.	2.1	39
119	Differential effect of carbamazepine and oxcarbazepine on excitatory synaptic transmission in rat hippocampus. <i>Synapse</i> , 2008, 62, 783-789.	0.6	14
120	Neuroprotective effect of hydrogen peroxide on an <i>in vitro</i> model of brain ischaemia. <i>British Journal of Pharmacology</i> , 2008, 153, 1022-1029.	2.7	34
121	Increased levels of d-aspartate in the hippocampus enhance LTP but do not facilitate cognitive flexibility. <i>Molecular and Cellular Neurosciences</i> , 2008, 37, 236-246.	1.0	79
122	Potential therapeutic usefulness of hydrogen peroxide in conditions of brain ischemia. <i>Medical Hypotheses</i> , 2008, 71, 162.	0.8	0
123	Synaptic plasticity in the basal ganglia: A similar code for physiological and pathological conditions. <i>Progress in Neurobiology</i> , 2008, 84, 343-362.	2.8	25
124	The Blockade of K ⁺ -ATP Channels has Neuroprotective Effects in an In Vitro Model of Brain Ischemia. <i>International Review of Neurobiology</i> , 2007, 82, 383-395.	0.9	29
125	The effect of inflammatory stimuli on NMDA-related activation of glutamine synthase in human cultured astroglial cells. <i>Neuroscience Letters</i> , 2005, 373, 184-188.	1.0	30
126	Kainate Receptors and Mossy Fiber LTP. <i>NeuroToxicology</i> , 2005, 26, 769-777.	1.4	36

#	ARTICLE	IF	CITATIONS
127	Synthesis and Pharmacology of Willardiine Derivatives Acting as Antagonists of Kainate Receptors. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 7867-7881.	2.9	51
128	The Protective Effect of Superoxide Dismutase Mimetic M40401 on Balloon Injury-Related Neointima Formation: Role of the Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 311, 44-50.	1.3	37
129	Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist. <i>Neuropharmacology</i> , 2004, 47, 46-64.	2.0	92
130	The protective effect of M40401, a superoxide dismutase mimetic, on post-ischemic brain damage in Mongolian gerbils. <i>BMC Pharmacology</i> , 2003, 3, 8.	0.4	16
131	The role of oxidative stress in paraquat-induced neurotoxicity in rats: protection by non peptidyl superoxide dismutase mimetic. <i>Neuroscience Letters</i> , 2003, 335, 163-166.	1.0	69
132	A Role for Ca ²⁺ Stores in Kainate Receptor-Dependent Synaptic Facilitation and LTP at Mossy Fiber Synapses in the Hippocampus. <i>Neuron</i> , 2003, 39, 327-341.	3.8	168
133	Dexamethasone Inhibits the Inducible Bioconversion of Glyceryl Trinitrate to Nitric Oxide. <i>Journal of Cardiovascular Pharmacology</i> , 2002, 39, 544-551.	0.8	1
134	Abnormal Expression of Neuronal Nitric Oxide Synthase Triggers Limbic Seizures and Hippocampal Damage in Rat. <i>Biochemical and Biophysical Research Communications</i> , 2002, 291, 255-260.	1.0	30
135	Excitotoxic Mechanisms of Apoptosis in the Mammalian Visual System Following Monocular Visual Deprivation. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2002, 91, 153-157.	0.0	4
136	The contribution of oxidative stress in apoptosis of human-cultured astroglial cells induced by supernatants of HIV-1-infected macrophages. <i>Journal of Leukocyte Biology</i> , 2002, 71, 65-72.	1.5	30
137	Central cardiovascular responses induced by interleukin 1 β and tumor necrosis factor α infused into nucleus tractus solitarii, nucleus parabrachialis medialis and third cerebral ventricle of normotensive rats. <i>Neuroscience Letters</i> , 2001, 314, 53-56.	1.0	7
138	HIV-1 Coat Glycoprotein gp120 Induces Apoptosis in Rat Brain Neocortex by Deranging the Arachidonate Cascade in Favor of Prostanoids. <i>Journal of Neurochemistry</i> , 2001, 75, 196-203.	2.1	35
139	Evidence that increases of mitochondrial immunoreactive IL-1 β by HIV-1 gp120 implicate in situ cleavage of pro-IL-1 β in the neocortex of rat. <i>Journal of Neurochemistry</i> , 2001, 78, 611-618.	2.1	29
140	Apoptosis in the Dorsal Lateral Geniculate Nucleus after Monocular Deprivation Involves Glutamate Signaling, NO Production, and PARP Activation. <i>Biochemical and Biophysical Research Communications</i> , 2000, 278, 360-367.	1.0	19
141	Profile of gantenerumab and its potential in the treatment of Alzheimer's disease [Corrigendum]. <i>Drug Design, Development and Therapy</i> , 0, , 569.	2.0	0